Find out how the Opto Plasma B Discovery workflow simplifies and dramatically reduces the time needed to down-select potential lead candidates, even for difficult membrane proteins.
Find out how Abveris is transforming their antibody discovery processes with the Beacon® optofluidic system.
At the 2021 AE&T EU conference, Tracey Mullens, CEO of Abveris, and Brian Walters, CEO of Genovac, joined John Proctor, SVP Antibody Therapeutics, for a discussion about the evolving landscape of antibody therapeutics, the technologies they have turned to address today’s complex targets, and how they are preparing for tomorrow’s challenges.
Learn how antibody discovery is changing in today’s therapeutic space. Case studies presented by Abveris highlight accelerated development of next-generation antibody therapeutics.